uniQure
QURE
Market cap $496M

13.00 USD

+3.61

38.45%

At close Apr 17, 4:00 PM EDT

After hours

13.24

+0.24

1.85%

1 day

38.45%

5 days

51.16%

1 month

-10.53%

3 months

-7.47%

6 months

107.01%

Year to date

-27.98%

1 year

178.37%

5 years

-76.76%

10 years

-51.80%

About: uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.

Employees: 209

Healthcare Biotechnology

0

Funds holding %

of 7,407 funds

0

Analysts bullish %

of 4 analysts

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

292% more call options, than puts

Call options by funds: $51.5M | Put options by funds: $13.2M

281% more capital invested

Capital invested by funds: $193M [Q3] → $734M (+$541M) [Q4]

33% more first-time investments, than exits

New positions opened: 36 | Existing positions closed: 27

5.53% more ownership

Funds ownership: 79.83% [Q3] → 85.36% (+5.53%) [Q4]

5% more funds holding

Funds holding: 130 [Q3] → 137 (+7) [Q4]

23% less repeat investments, than reductions

Existing positions increased: 36 | Existing positions reduced: 47

See Fund Rankings

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$24

85%

upside

Avg. target

$41

212%

upside

High target

$70

438%

upside

4 analyst ratings

3 positive

75%

1 neutral

25%

0 negative

0%

Chardan Capital Daniil Gataulin 16% 1-year accuracy 8 / 49 met price target	192%upside $38	Buy Maintained	1 Apr 2025
HC Wainwright & Co. Patrick Trucchio 15% 1-year accuracy 28 / 186 met price target	438%upside $70	Buy Reiterated	4 Mar 2025
Wells Fargo Yanan Zhu 12% 1-year accuracy 2 / 17 met price target	131%upside $30	Equal-Weight Maintained	28 Feb 2025
RBC Capital Luca Issi 7% 1-year accuracy 4 / 55 met price target	85%upside $24	Outperform Reiterated	21 Jan 2025

See Analyst Rankings

Financial journalist opinion

Why Is Gene Therapy Developer uniQure Stock Trading Higher On Thursday?

The U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation to uniQure N.V.'s QURE AMT-130 for Huntington's disease on Thursday

Why Is Gene Therapy Developer uniQure Stock Trading Higher On Thursday?

uniQure Announces FDA Breakthrough Therapy Designation Granted to AMT-130 for the Treatment of Huntington's Disease

~ Breakthrough Therapy designation based on clinical evidence from Phase I/II trials showing meaningful slowing of disease progression ~

uniQure Announces FDA Breakthrough Therapy Designation Granted to AMT-130 for the Treatment of Huntington's Disease

Zacks Investment Research

UniQure (QURE) Reports Q4 Loss, Misses Revenue Estimates

UniQure (QURE) came out with a quarterly loss of $1.50 per share versus the Zacks Consensus Estimate of a loss of $0.44. This compares to loss of $1.53 per share a year ago.

UniQure (QURE) Reports Q4 Loss, Misses Revenue Estimates

uniQure Announces 2024 Financial Results and Highlights Recent Company Progress

~ Announced alignment with the U.S. Food and Drug Administration (FDA) on key elements of the Accelerated Approval pathway for AMT-130 in Huntington's disease; Initiated preparations for a potential Biologics License Application (BLA) submission ~

uniQure Announces 2024 Financial Results and Highlights Recent Company Progress

uniQure N.V.: A Potential Huntington's Play

uniQure's stock surged in December due to positive data around its Huntington's disease candidate AMT-130, clearing the way for potential accelerated FDA approval without another trial. The company's gene therapy Hemgenix, approved for hemophilia B, and three new clinical programs, including AMT-191, AMT-162, and AMT-260, bolster its pipeline. Cost-cutting measures and strategic financing have extended uniQure's operating runway through 2Q28, with significant analyst support and price targets up to $70 a share.

uniQure N.V.: A Potential Huntington's Play

uniQure: Gene Therapy Specialist Looks Set For Upside As Huntington's Approval Beckons

uniQure's gene therapy AMT-130 for Huntington's Disease shows promising clinical data, with an 80% reduction in disease progression, positioning it for potential FDA approval. Despite past commercial failures, uniQure's current market cap of ~$715m appears undervalued given AMT-130's estimated peak sales potential of ~$2bn. The company has a solid cash position to fund AMT-130's launch, with $251m in cash and $183m in securities, despite a $100m net loss in the first 9m of 2025.

uniQure: Gene Therapy Specialist Looks Set For Upside As Huntington's Approval Beckons

uniQure/ CSL Behring's Hemophilia Gene Therapy Shows Sustained Efficacy and Safety At Four Years

CSL Limited CSLLY and uniQure Inc QURE announced the four-year results from the pivotal HOPE-B study confirming the long-term durability and safety of a one-time infusion of Hemgenix (etranacogene dezaparvovec-drlb) for adults hemophilia B patients.

uniQure/ CSL Behring's Hemophilia Gene Therapy Shows Sustained Efficacy and Safety At Four Years

CSL Behring's Gene Therapy HEMGENIX® (etranacogene dezaparvovec-drlb) Four Years Post-Infusion Data Continue to Show Sustained Efficacy and Safety in Adults with Hemophilia B

94 percent of patients eliminated factor IX prophylaxis and remained free of continuous prophylaxis through four years post-treatment Mean factor IX activity levels were sustained at near normal levels of 37% through four years post-treatment, reinforcing the efficacy of HEMGENIX in the treatment of hemophilia B Phase 3 HOPE-B data showed that a one-time treatment with HEMGENIX provided long-term bleed protection as mean adjusted annualized bleeding rate (ABR) for all bleeds was reduced by approximately 90% from lead-in as compared to year four KING OF PRUSSIA, Pa. , Feb. 7, 2025 /PRNewswire/ -- Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) today announced the four-year results from the pivotal HOPE-B study confirming the long-term durability and safety of a one-time infusion of HEMGENIX® (etranacogene dezaparvovec-drlb) for adults living with hemophilia B.

CSL Behring's Gene Therapy HEMGENIX® (etranacogene dezaparvovec-drlb) Four Years Post-Infusion Data Continue to Show Sustained Efficacy and Safety in Adults with Hemophilia B

uniQure Announces Completion of Enrollment in the First Cohort and Favorable Recommendation from the Independent Data Monitoring Committee for its Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease

~ Independent Data Monitoring Committee recommends proceeding with dosing of second cohort after planned safety assessment ~

uniQure Announces Completion of Enrollment in the First Cohort and Favorable Recommendation from the Independent Data Monitoring Committee for its Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease

uniQure Announces Favorable Recommendation from Independent Data Monitoring Committee for its Phase I/II EPISOD1 Clinical Trial of AMT-162 for the Treatment of SOD1-ALS

~ Independent Data Monitoring Committee Recommends Proceeding with Dose Escalation After Planned Safety Assessment of First Dose Cohort ~

uniQure Announces Favorable Recommendation from Independent Data Monitoring Committee for its Phase I/II EPISOD1 Clinical Trial of AMT-162 for the Treatment of SOD1-ALS

See News Rankings

Charts implemented using Lightweight Charts™